Back to the main directory
EarningsReview / Equity
- Good number and in-line guidance: first take by BNP Paribas
- Acciona - Mixed 2H25 results: Nordex to the rescue by JB Capital Markets
- Better Collective - Back on the growth track by Danske Bank Equity Research
- Gestamp - 4Q25 underlying EBITDA in line despite lower revenues by JB Capital Markets
- Strong set of 2025 results by BNP Paribas
- Q4 miss, guidance below, shares vulnerable given valuation by BNP Paribas
- Not throwing the baby out with the bathwater by BNP Paribas
- 4Q25 results: 4Q beat with better POP growth, FY26/27 guide in-line at mid-point, see shares up 2-3% by BNP Paribas
- Q4/H2 in-line, FY26 cEBIT guide 2% below by BNP Paribas
- Strong beat; 2026 Outlook reiterated by BNP Paribas
- Q4 2025: Conservative earnings recognition with a buyback sweetener by BNP Paribas
- Abionyx Pharma - Point sur l’activité et la trésorerie à fin 2025 by MidCap Partners
- Hipay - CA 2025 by MidCap Partners
- WeSports Group - “It’s in the game” by Danske Bank Equity Research
- Nanoform - Commercial ASD projects moving on by Danske Bank Equity Research
- Vallourec SA - Une solide fin d’exercice by MidCap Partners
- Teleperformance - Publication en ligne, outlook prudent, pivot managérial majeur. by MidCap Partners
- Bonduelle - Abaissement des objectifs de rentabilité by MidCap Partners
- Valeo SE - Une publication solide by MidCap Partners
- Cellnex Telecom - In-line guidance with no relevant deviations in the results by JB Capital Markets
- Qt Group - AI threat far from fading by Danske Bank Equity Research
- FY 2025 results first-take: Strong end to the year, but 2026 and midterm outlook do not suggest cons upgrades by BNP Paribas
- First take on “Beat 30”: A new capex plan to drive higher growth by BNP Paribas
- INVEST SECURITIES - SOPRA STERIA : Rassurant, suffisant pour stopper le derating ? - ACHAT, OC 244€ vs 242€ by Invest Securities
- FCC: RDOS. 4T’25 (ANÁLISIS BANCO SABADELL) by Sabadell